Home Search

CARA - search results

If you're not happy with the results, please do another search

Cara Therapeutics, Inc. (CARA) to Webcast Presentation

Cara Therapeutics to Webcast Presentation at the Canaccord Genuity 37th Annual Growth Conference Cara Therapeutics, Inc. (CARA), a biotechnology company focused on developing and commercializing...

Cara Therapeutics, Inc. (CARA) Announces Summary Data From Phase 1 Trial of Oral CR845

Cara Therapeutics Announces Summary Data From Phase 1 Trial of Oral CR845 in Hemodialysis Patients with Chronic Kidney Disease Cara Therapeutics, Inc. (CARA), a biopharmaceutical...

Cara Therapeutics, Inc. (CARA) Reports Continuation of Phase 3 Trial of I.V. CR845

Cara Therapeutics Reports Continuation of Phase 3 Trial of I.V. CR845 in Postoperative Pain Following Interim Assessment - Trial will continue to test two doses...

$CARA to Present at the 17th Annual Conference on Pain Therapeutics

Cara Therapeutics to Present at the 17th Annual Conference on Pain Therapeutics Dr. Joseph Stauffer to deliver opening remarks and discuss kappa opioid receptor agonists...

$CARA breached its 50 day moving average in a Bullish Manner

CARA Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CARA-US : May 15, 2017 CapitalCube Capital Cube•May 15, 2017 CARA Therapeutics, Inc....

$CARA to Announce First Quarter 2017 Financial Results on May 4, 2017

Cara Therapeutics to Announce First Quarter 2017 Financial Results on May 4, 2017 Cara Therapeutics, Inc. (CARA), a biotechnology company focused on developing and commercializing...

$CARA Positive Data From Quantitative Phase 1 Trial

Cara Therapeutics Announces Positive Data From Quantitative Phase 1 Trial Measuring Respiratory Safety of I.V. CR845 Cara Therapeutics, Inc. (CARA), a biopharmaceutical company focused on...
marijuana stocks

$CARA Research Reports

Today's Research Reports on Biotech Stocks to Watch: Cara Therapeutics and Incyte The volatile Biotech Industry has continued to be home to some of the...

$CARA Announces Positive Top-Line Data From Part A of Phase 2/3 Trial

Cara Therapeutics Announces Positive Top-Line Data From Part A of Phase 2/3 Trial of I.V. CR845 in Chronic Kidney Disease-Associated Pruritus Met primary endpoint with...

$CARA Form 10-K

Form 10-K for CARA THERAPEUTICS, INC. 10-Mar-2017 Annual Report Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations.You should read the following discussion...

Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Marijuana Stocks, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com